STATE MEDICAID P&T COMMITTEE MEETING

THURSDAY, August 15, 2013
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 128

MINUTES

Committee Members Present:

Kort Delost, R.Ph.
Lisa Hunt, R.Ph.
Roger Martenau, M.D.
Beth Johnson, R.Ph.
Elizabeth Young, Pharm.D.

Committee Members Excused:

Ellie Brownstein, M.D.
Bernadette Kiraly, M.D.
Julia Ozbolt, M.D.
Jameson Rice, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Timothy Morley R.Ph.
Trevor Smith, CPhT
Robyn Seely, Pharm.D.
Richard Sorenson RN

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Other Individuals Present:

Scott Larson, BMS
Michele Puyear, Gilead
Alan Bailey, Pfizer
Kim Eggert, Gilead
Lisa Jenson, Gilead
Paul Bonham, NovoNordisk

Meeting conducted by: Kort Delost

1. Review and Approval of July minutes: Beth Johnson moved to approve the minutes, Roger Martenau seconded the motion. Motion approved unanimously.

2. Housekeeping: Lisa Hunt reported that September 1st will be the next PDL update. She also asked the committee if they had decided upon a version of a Roberts Rules of Order they would like to implement in P&T meetings. Members said they would like to use the official rules as a guideline, but not for strict enforcement. The rules will be included in training packets for new committee members.

3. Drug Utilization Review (DUR) Board update: Robyn Seely stated that the DUR board did not have a meeting during August, and in September, the board will discuss TZDs.

4. Melissa Archer presented materials about the sulfonylureal drug class. She included first and second generation drugs and extended release formulation. Instruction related to

safety and efficacy, usage for each product based on disease state, studies and trials, and historical claim data for each drug was presented. Recommendation was that one second generation agent be considered for inclusion on the PDL. Overall the choice of anti-diabetes therapy should be based on individual patient characteristics, cost, potential adverse effects and patient preference.

5. No public comment

6. Board discussion of first generation sulfonylureals

    a. Kort Delost asked for opinions about the first generation drugs

    b. Beth Young and Kort Delost mentioned that there is little to no usage in the first generation. Kort Delost went on to say his experience in the pharmacy has not seen usage for around 5 years.

    c. Melissa Archer says that Medicaid utilization for first generation drugs has been zero since 2011.

    d. Beth Young makes a motion to not include the first generation sulfonylureal drugs for inclusion in the PDL based on safety and efficacy. Beth Johnson seconds the motion. All in favor.

7. Board discussion of second generation sulfonylureal short acting products

    a. Discussion about the second generation drugs all being equally safe and effective

    b. Beth Young makes a motion that the second generation products are equally safe and effective. Roger Martenau seconds the motion. All in favor.

8. Board discussion of second generation sulfonylureal long acting products

    a. Beth Johnson mentioned that for patients who are admitted to the hospital, only the short acting is used based on a recent decision, but for patients obtaining medications in a pharmacy, the long acting drugs could be beneficial

    b. Beth Young says that the short and long acting products are equally safe and effective.

    c. Lisa Hunt clarifies how the drugs are put on the PDL after the safety and efficacy decision by the P&T committee.

    d. Motion by Roger Martenau to include the long acting products in the PDL as they are equally safe and effective as the short acting products. Motion is seconded by Elizabeth Young. All in favor.

9. Board discussion of sulfonylurea combination products

a. Lisa Hunt says that Medicaid has a policy that allows combination products to be secondary to taking the products individually, but Medicaid may prefer a combination product if the price difference is beneficial to Medicaid.

b. Beth Young says that the main benefit of a combination product is to reduce pill burden on a patient.

c. Kort Delost says that there are no studies showing that a combination product is more safe or effective than individual products.

d. Beth Johnson makes a motion to consider combination products for the inclusion on the PDL if the drug price is economically beneficial to Utah Medicaid. Roger Martenau seconds the motion. All in favor.

10. Next meeting is scheduled for Sept 19, 2013 where anticoagulants and erythropoiesis stimulating agents will be discussed.

11. Beth Johnson made a motion to close the meeting, Beth Young seconded the motion, all approved.

12. Meeting adjourned.

Next Meeting Set for Thursday, Sept 19, 2013 - anticoagulants and erythropoiesis-stimulating agents
Minutes prepared by Trevor Smith
Recording available upon request, send email to medicaidpharmacy@utah.gov